

## Amendments to the Claims

1. (Canceled).
2. (Currently amended). A method ~~according to claim 1~~ of monitoring the effect of in vivo administration of a cathepsin S inhibitor to a subject, comprising the steps of:
  - a) taking a blood sample of the subject ~~treated~~;
  - b) purifying the white blood cells from said sample;
  - c) making whole cell lysates of the purified white blood cells; and
  - d) analyzing the lysates for presence of a p10Ii fragment ~~an intermediate degradation product~~ of invariant chain (Ii) by a suitable assay method.
3. (Currently amended). A method of monitoring the effect of in vivo administration of a cathepsin S inhibitor to a subject as defined in ~~according to claim 2~~ wherein the suitable assay method in step (d) is Western blotting or ELISA enzyme-linked immunosorbent assay.
4. (Currently amended). A method of monitoring the effect of in vivo administration of a cathepsin S inhibitor to a subject as defined in ~~according to claim 1~~ 2 wherein the ~~intermediate degradation product of invariant chain (Ii) is the p10Ii fragment~~ subject is a human.